Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120223 | 0.97 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4119132 | 0.96 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL187156 | 0.94 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4120876 | 0.87 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL16569484 | 0.85 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL4127225 | 0.85 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL31216597 | 0.84 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL31297853 | 0.83 | SMYD2 (0.32) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL17768518 | 0.83 | ABL1 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL8612535 | 0.81 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241408-A | Trifluoro methyl sulfide molecule as HIF2a inhibitor | 维眸生物科技(浙江)有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-117321052-A | Alkyne compound as HPK1 inhibitor and application thereof | 南京再明医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2022228522-A1 | ALKYNE COMPOUND AS HPK1 INHIBITOR AND USE THEREOF | 江苏先声药业有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-11434205-B2 | Substituted imidazole carboxylate derivatives and the use thereof | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3747869-A1 | SUBSTITUTED IMIDAZOLE FORMATE DERIVATIVE AND USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200369621-A1 | SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-109776512-A | N-substituted imidazole formate derivative and application thereof | 成都安诺晨创医药科技有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-3221300-B1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-12-14 | — | — | US | disclosed |
| EP-3221300-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079688-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-26 | — | — | WO | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SMYD2 3091/4885CYP3A4 157/4885HTT 3905/4885 |
| US-11434205-B2 | Substituted imidazole carboxylate derivatives and the use thereof | SLC6A11, SLC6A13, SLC6A1 | SMYD2 3646/4885CYP3A4 12/4885HTT 3786/4885 |
| US-20200369621-A1 | SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF | SLC6A13, SLC6A11, SLC6A1 | SMYD2 2738/4885CYP3A4 11/4885HTT 3376/4885 |
| US-20170355687-A1 | ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES | CYP8B1, TUBB, DRD3 | SMYD2 1795/4885CYP3A4 1095/4885HTT 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.